Germany · Delayed Price · Currency is EUR AlzChem Group AG Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profitability grew strongly in Q1 2026, led by specialty ingredients and robust demand in nutrition and defense. Major CapEx projects are on track, and full-year guidance is confirmed despite some cost pressures, with positive cash flow and a strong equity position.
Fiscal Year 2025
-
Sales and EBITDA grew year-over-year, driven by specialty chemicals and strong demand in human nutrition and defense. Major investments in creatine and Nitroguanidine will fuel double-digit growth from 2027, with a robust cash position and increased dividend.
-
Specialty chemicals drove strong Q3 and nine-month growth, with EBITDA up 12% and margin at 20.3%. Capacity expansions, new product launches, and a robust outlook for full-year sales and earnings highlight continued momentum, despite FX and energy cost risks.
-
Sales and EBITDA grew in H1 2025, led by Specialty Chemicals, especially creatine and custom synthesis. CapEx and customer grants support major expansions, while risks include energy costs, Chinese competition, and regulatory uncertainty. Guidance for 2025 is confirmed.
-
Specialty chemicals drove Q1 2025 growth with higher EBITDA and margin, offsetting declines in basics and intermediates. Major investments and customer prepayments strengthened cash flow, and full-year guidance for record sales and EBITDA is confirmed.
Fiscal Year 2024
-
Record sales and EBITDA were achieved in 2024, driven by Specialty Chemicals, with strong cash flow and a robust balance sheet. 2025 guidance anticipates further growth, led by volume increases in key specialty products and continued investment in capacity expansion.
-
Q3 saw strong revenue and EBITDA growth, driven by specialty chemicals, with net income up 66% year-over-year. Major investments in Germany and the U.S. are pre-financed, supporting future growth, while guidance for 2024 is confirmed with EBITDA expected above €100 million.